Humira (Adalimumab) | EyeKnow O.D.

Approved uses

Non-infectious intermediate, posterior and panuveitis, adults

80 mg subcutaneously once, then 40 mg every other week starting one week later

The reason an optometrist opens this card; the rest of its label is rheumatology

Non-infectious uveitis, children aged 2 and over

10 mg every other week at 10 to under 15 kg; 20 mg every other week at 15 to under 30 kg; 40 mg every other week at 30 kg and above

Contraindications

None.

Available Forms

Injection, pre-filled pen and syringe delivering 10 mg, 20 mg, 40 mg or 80 mg of adalimumab subcutaneously.

Mechanism of Action

Adalimumab binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement. Adalimumab does not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Elevated concentrations of TNF are found in the synovial fluid of patients with RA, JIA, PsA, and AS and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of these diseases. Increased concentrations of TNF are also found in psoriasis plaques.